Concentratie van clindamycine in bloed bij patiënten met overgewicht
Recruiting
- Conditions
- infection clindamycin overweight obesity pharmacokinetics
- Registration Number
- NL-OMON20286
- Lead Sponsor
- Gelre Hospitals, Apeldoorn/ZutphenAlbert Schweitzerlaan 31 7334 DZ Apeldoorn
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Age > 18 years
- Treatment at regular dosing intervals with intravenous or oral clindamycin for at least 48 hours on day of blood sampling. Subject can be included twice if route of administration changes.
Exclusion Criteria
- Administration of medication with a known pharmacokinetic interaction ( e.g. rifampicin, HIV protease inhibitors.
- Inability to understand the nature of the trial and the procedures required.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method on-linear mixed effect pharmacokinetic model
- Secondary Outcome Measures
Name Time Method - Variability of plasma protein binding<br /><br>- Pharmacokinetic target achievement